1. The Dual Role of Senescence in Pancreatic Ductal Adenocarcinoma
Angelo Porciuncula, Cristina Hajdu and Gregory David
2. Small Molecule Targeting of BET Proteins in Cancer
Christopher A. French
3. H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer
Jessica N. Nichol, Daphné Dupéré-Richer, Teresa Ezponda, Jonathan D. Licht, Wilson H. Miller and Jr.
4. AEG1/MTDH/LYRIC: A Promiscuous Protein Partner Critical in Cancer, Obesity and CNS Diseases
Luni Emdad, Swadesh K. Das, Bin Hu, Timothy Kegelman, Dong-chul Kang, Seok-Geun Lee, Devanand Sarkar and Paul B. Fisher
5. Role of the RB Interacting Proteins in Stem Cell Biology
M. Mushtaq, H. Viñas Gaza and E.V. Kashuba
6. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells (CSCs)
Sarmistha Talukdar, Luni Emdad, Swadesh K. Das, Devanand Sarkar and Paul B. Fisher
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
- Provides information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.
- No. of pages:
- © Academic Press 2016
- 19th July 2016
- Academic Press
- eBook ISBN:
- Hardcover ISBN:
Praise for the Serial
"This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences." --American Scientist
"Excellent, highly informative, in-depth reviews…expertly written, up-to-date, and well-referenced." --Journal of Medicinal Chemistry
"This is a series that has a long tradition of excellence in the field of cancer biology." --Doody’s Publishing Reviews
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.
Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 600 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).
VCU Institute of Molecular Medicine, VA, USA